An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Active Date:
February 19, 2018
IRB Number:
INSIGHT
Condition/Disease:
Lung Cancer
Lead Researcher:
Maria Quejada, MD
Location:
Edward Cancer Center - Naperville
Purpose:
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
Sponsor: Biodesix, Inc.
https://clinicaltrials.gov/ct2/show/NCT03289780
Eligibility:
EGFR mutation status either unknown and subject is willing to provide samples for GeneStrat testing or wildtype
willingness to provide serum samples for VeriStrat testing
no prior malignancy within 2 years (except for adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix, superficial bladder cancer, or early stage prostate cancer, without evidence of recurrence)
Time Commitment:
18 months
Status:
Accepting Participants
Current Trial Type:
Observational
Contact Name:
Sofia Mikac, BSN
Phone:
331-221-2168
Fax:
630-646-6074
Alternate Phone:
630-646-6072